Bulletin
Investor Alert

New York Markets Close in:

April 22, 2021, 8:07 a.m. EDT

Diagnostic Radiopharmaceuticals & Contrast Media Market 2021: Industry Analysis, Geographical Segmentation, Drivers, Challenges, Trends Forecasts By 2024

Diagnostic Radiopharmaceuticals & Contrast Media Market report strategically analyzes each submarket with respect to individual growth trend and their contribution to the market.

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Apr 22, 2021 (The Expresswire) -- “ Diagnostic Radiopharmaceuticals and Contrast Media Market ”report give an insightful analysis of the market development variables and drivers, the geographies have been exclusively examined in terms of the parameters such as production, market share in terms of the manufacturers as well as with respects to application and type. Diagnostic Radiopharmaceuticals and Contrast Media market observes the performance of the market with depth analysis of market scope and stake, revenue, supply and demand, applications, trends. It shows manufacturing capacity and Diagnostic Radiopharmaceuticals and Contrast Media in market price during the forecast period.

Get a Sample Copy of the Report - https://www.absolutereports.com/enquiry/request-sample/13999529

Market Overview:

Key Market Trends:

Cardiology Sub-segment Captured the Largest Market Share and is Expected to Retain its Dominance

The major factor driving the growth of the market is the rising prevalence of cardiovascular diseases over the world. According to the estimates of the World Health Organization (WHO), in 2016, 17.9 million people died from CVDs. SPECT, which stands for single photon emission computed tomography, is a non-invasive procedure that can accurately identify areas of abnormal myocardial perfusion. It is also used to determine the functional capacity of the heart muscle and is able to separate living tissue from an irreversibly damaged tissue. This diagnostic procedure helps physicians find out if there are blockages in the coronary (heart) arteries, as well as to determine if the patient should undergo a coronary angiogram. In SPECT, cardiac-specific radiopharmaceuticals, such as 99mTc-tetrofosmin (Myoview, GE healthcare), 99mTc-sestamibi (Cardiolite, Bristol-Myers Squibb), or Thallium-201 chloride are administered. Hence, factors, such as the rising prevalence of cardiovascular diseases and technological advancements in the field of diagnostics, are expected to drive the growth of the market over the forecast period.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

North America dominated the overall diagnostic radiopharmaceuticals and contrast media market, with the United States accounting for the major contributor to the market. The US diagnostic radiopharmaceuticals and contrast media market is anticipated to continue its expansion over the forecast period. The first gadolinium-based contrast agent was approved in the United States. Four agents were approved in the United States in the past decade, and they have set a string trend in the industry to continue to find more efficient, accurate, and safe agents.

The contrast media sales are expected to increase in the United States in the coming years. Among the different imaging modalities, sales of contrast media for the ultrasound market are likely to have a considerable growth rate. Diagnostic radioisotopes are a significant component of the US economy. Increase in chronic cardiac and neurological diseases is the primary driving factor for the market growth in the United States. Hence, the North American diagnostic radiopharmaceuticals and contrast media market is expected to retain its dominance over the forecast period.

Inquire or Share Your Questions If Any Before the Purchasing This Report:- https://www.absolutereports.com/enquiry/pre-order-enquiry/13999529

Major Key Players are as Follows

Scope of the Report:

Geographical Regions:

- United States - Canada - Mexico - United Kingdom - Germany - France - Italy - Spain - China - Japan - - Australia - South Korea - GCC - South Africa - Brazil - Argentina.

Topics such as sales and sales revenue overview, production market share by product type, capacity and production overview, import, export, and consumption are covered under the development trend section of the Diagnostic Radiopharmaceuticals and Contrast Media market report.

Get a Sample Copy of the Diagnostic Radiopharmaceuticals and Contrast Media Market Report 2021

Reasons to Purchase Diagnostic Radiopharmaceuticals and Contrast Media Market Report Covered:

Detailed TOC of Diagnostic Radiopharmaceuticals and Contrast Media Market - Growth, Trends, and Forecast (2019 - 2024)

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Technology Advancements in Medical Imaging
4.2.2 Increasing Demand for Image-guided Procedures and Diagnostics
4.2.3 High Prevalence of Cancers and Cardiac Diseases
4.3 Market Restraints
4.3.1 High Costs of the Techniques- Not Easily Affordable
4.3.2 Limited Health Insurance Coverage
4.3.3 Short Half-life of Radiopharmaceuticals
4.4 Industry Attractiveness Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 Radiopharmaceuticals
5.1.1 By Type of Imaging Modality
5.1.1.1 SPECT
5.1.1.1.1 Tc-99
5.1.1.1.2 Tl-201
5.1.1.1.3 Ga-67
5.1.1.1.4 I-123
5.1.1.1.5 Other SPECTs
5.1.1.2 PET
5.1.1.2.1 F-18
5.1.1.2.2 Rb-82
5.1.1.2.3 Other PETs
5.1.2 By Application
5.1.2.1 Diagnostic Application
5.1.2.1.1 SPECT Applications
5.1.2.1.1.1 Cardiology
5.1.2.1.1.2 Neurology
5.1.2.1.1.3 Thyroid
5.1.2.1.1.4 Other SPECT Applications
5.1.2.1.2 PET Application
5.1.2.1.2.1 Oncology
5.1.2.1.2.2 Cardiology
5.1.2.1.2.3 Neurology
5.1.2.1.2.4 Other PET Applications
5.1.2.2 Therapeutic Application
5.1.2.2.1 Thyroid
5.1.2.2.2 Lymphoma
5.1.2.2.3 Endocrine Tumors
5.1.2.2.4 Other Therapeutic Applications
5.2 Contrast Media
5.2.1 By Application
5.2.1.1 Ionizing Radiation-based Radioimaging
5.2.1.2 Non-Ionizing Radiation-based Radioimaging
5.2.2 By Procedure
5.2.2.1 X-ray/Computed Tomography (CT)
5.2.2.1.1 Iodinated Contrast Media Ionic
5.2.2.1.2 Iodinated Contrast Media Non-Ionic
5.2.2.1.3 Barium-based Contrast Media
5.2.2.2 Magnetic Resonance Imaging (MRI)
5.2.2.2.1 Gadolinium-based Contrast Media
5.2.2.2.2 Other Magnetic Resonance Imaging
5.2.2.3 Ultrasound
5.2.3 By Indication
5.2.3.1 Cardiovascular Disease
5.2.3.2 Oncology
5.2.3.3 Gastrointestinal
5.2.3.4 Disorders
5.2.3.5 Neurological
5.2.3.6 Disorders
5.2.3.7 Other Indications
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2
5.3.2.1 United Kingdom
5.3.2.2 Germany
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bioclinica
6.1.2 Bio-Optronics Inc.
6.1.3 DATATRAK International Inc.
6.1.4 ERT Clinical
6.1.5 IBM Watson Health
6.1.6 Medidata Solutions Inc.
6.1.7 MedNet Solutions Inc.
6.1.8 Oracle Corporation
6.1.9 Parexel International Corporation
6.1.10 ArisGlobal

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Purchase this Report (Price 4250 USD for a Single-User License) at https://www.absolutereports.com/purchase/13999529

Contact Info:

Name: Ajay More

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.